David Randall Blair, MD, PHD
Clinical Genetics (M.D.) · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Office
- 1
Offices
1 location
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Blair’s office at (415) 476-5001 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A159073 · Current
Licensed to practise in California · since 2018 · expires 2028-10-31 · University of Chicago, Pritzker School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Medical Genetics and Genomics - Clinical Genetics and Genomics (MD)
- American Board of Pediatrics - Pediatrics
Medicaid work
$1,868 in 2023
Medicaid paid $1,868 for 24 billed services this clinician did in 2023, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 12 | $1,723 |
| Telehealth transmission, per minute, professional services bill separately | 12 | $144 |
| 2023 | 24 | 2 | 12 | $1,868 |
Drugs they prescribed that Part D paid
$572,608
Pharmacies billed $572,608 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 54) in 2024. At or below the middle of the specialty; the typical pediatric medicine clinician is at 0%.
0 generic and 54 brand-name prescriptions · $572,608 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Vpriv | 12 | $426,371 | $35,531 |
| Fabrazyme | 19 | $129,950 | $6,839 |
| Sodium Chloride | 11 | $6 | $1 |
Year by year
| 2024 | 54 | None | 0% (0) | 100% | $572,608 |
| 2023 | 54 | None | 0% (0) | 94% | $378,931 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Fabrazyme | 19 | $108,238 | $5,697 |
| Cystadane | 15 | $57,372 | $3,825 |
Money from drug and device companies
$1,484 in 2025
A payment is not proof that care is biased.
| Regeneron Pharmaceuticals | None | $1,484 | 7 payments
|
See all 7 published payments
| Regeneron Pharmaceuticals | Meals · 2025-01-16 | None | $9 |
| Regeneron Pharmaceuticals | Travel · 2025-01-15 | None | $168 |
| Regeneron Pharmaceuticals | Travel · 2025-01-15 | None | $90 |
| Regeneron Pharmaceuticals | Travel · 2025-01-14 | None | $181 |
| Regeneron Pharmaceuticals | Travel · 2025-01-14 | None | $210 |
| Regeneron Pharmaceuticals | Travel · 2025-01-09 | None | $26 |
| Regeneron Pharmaceuticals | Travel · 2025-01-09 | None | $800 |
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| BioMarin Pharmaceutical Inc. · Voxzogo 1.2mg · 2024 | Their institution | $51,109 |
| BioMarin Pharmaceutical Inc. · Voxzogo 1.2mg · 2025 | Their institution | $20,015 |
| GENZYME CORPORATION · A Phase 2/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Repeat Dose Study To Evaluate the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency · 2023 | Their institution | $12,303 |
| GENZYME CORPORATION · A Phase 2/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Repeat Dose Study To Evaluate the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency · 2024 | Their institution | $7,956 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 74.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1972034841
- Licence
- CA A159073California A159073: Current · expires 2028-10-31
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207SG0201X (207SG0201X)
- Mailing address
- 550 16th St # 706, San Francisco, CA, 94158
- NPI first listed
- 2017-03-23
- NPI last updated
- 2020-07-07
- NPI record certified
- 2020-07-07
This is when the NPI record was last certified, not a medical board exam.